Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance

被引:169
作者
Miners, JO
McKinnon, RA
Mackenzie, PI
机构
[1] Flinders Med Ctr, Dept Clin Pharmacol, Adelaide, SA, Australia
[2] Flinders Univ S Australia, Sch Med, Adelaide, SA 5001, Australia
[3] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
关键词
genetic polymorphism; UDP-glucuronosyltransferase; glucuronidation;
D O I
10.1016/S0300-483X(02)00449-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
UDP-Glucuronosyltransferase (UGT), the microsomal enzyme responsible for glucuronidation reactions, exists as a superfamily of enzymes. Genetic polymorphism has been described for 6 of the 16 functional human UGT genes characterised to date, namely UGT 1A1, IA6, 1A7, 2B4, 2B7 and 2B15. Since glucuronidation is an essential pathway for the elimination of a myriad of xenobiotics and endogenous compounds, genetic polymorphism of UGT is potentially of toxicological and physiological importance. However, functional significance has only been convincingly demonstrated for genetic polymorphism of UGT1A1 Apart from impaired bilirubin glucuronidation, the mutations responsible for Gilbert syndrome also affect the elimination of a limited number of xenobiotics. It has been proposed on the basis of altered catalytic activity of mutants of UGT 1A6, 1A7 and 2B15 that genetic polymorphism of these forms may be of toxicological significance, but this is yet to be proven. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:453 / 456
页数:4
相关论文
共 21 条
[1]  
Ando Y, 2000, CANCER RES, V60, P6921
[2]   Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter:: A balanced polymorphism for regulation of bilirubin metabolism? [J].
Beutler, E ;
Gelbart, T ;
Demina, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :8170-8174
[3]   Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance [J].
Bhasker, CR ;
McKinnon, W ;
Stone, A ;
Lo, ACT ;
Kubota, T ;
Ishizaki, T ;
Miners, JO .
PHARMACOGENETICS, 2000, 10 (08) :679-685
[4]   THE GENETIC-BASIS OF THE REDUCED EXPRESSION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE-1 IN GILBERTS-SYNDROME [J].
BOSMA, PJ ;
CHOWDHURY, JR ;
BAKKER, C ;
GANTLA, S ;
DEBOER, A ;
OOSTRA, BA ;
LINDHOUT, D ;
TYTGAT, GNJ ;
JANSEN, PLM ;
ELFERINK, RPJO ;
CHOWDHURY, NR .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (18) :1171-1175
[5]   Molecular genetic basis of Gilbert's syndrome [J].
Burchell, B ;
Hume, R .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 14 (10) :960-966
[6]   Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications [J].
Ciotti, M ;
Marrone, A ;
Potter, C ;
Owens, IS .
PHARMACOGENETICS, 1997, 7 (06) :485-495
[7]  
Grant DJ, 2000, MOL CARCINOGEN, V29, P198, DOI 10.1002/1098-2744(200012)29:4<198::AID-MC1001>3.3.CO
[8]  
2-B
[9]   Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus:: functional consequences of three novel missense mutations in the human UGT1A7 gene [J].
Guillemette, C ;
Ritter, JK ;
Auyeung, DJ ;
Kessler, FK ;
Housman, DE .
PHARMACOGENETICS, 2000, 10 (07) :629-644
[10]   Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism [J].
Iyer, L ;
Hall, D ;
Das, S ;
Mortell, MA ;
Ramírez, J ;
Kim, S ;
Di Rienzo, A ;
Ratain, MJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) :576-582